NCT02785445

Brief Summary

The objectives of the Healthy.io Method Comparison and User Performance Study are:

  1. 1.To evaluate the performance of Dip.io Device in comparison to the ACON U500 Mission® U500 Urine Analyzer.
  2. 2.To evaluate the user performance of Dip.io Device under actual use conditions (home environment) based on a user questionnaire and rating scale.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
425

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Oct 2015

Typical duration for not_applicable

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2015

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

May 17, 2016

Completed
10 days until next milestone

First Posted

Study publicly available on registry

May 27, 2016

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2017

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2017

Completed
Last Updated

September 11, 2017

Status Verified

September 1, 2017

Enrollment Period

1.7 years

First QC Date

May 17, 2016

Last Update Submit

September 7, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • Exact and ±1 agreement to compared device

    The primary objective of the study is to evaluate the exact agreement and the ±1 color block match of the Dip.io compared to the predicate device, for each analyte concentration (block).

    Through study completion, an average of 1 month

Secondary Outcomes (1)

  • User performance

    Through study completion, an average of 1 month

Study Arms (1)

All participants (single arm)

OTHER

All study participants once enrolled into the study were asked to collect their midstream urine in the designated device urine cups. The urine sample was then tested sequentially; first by the Dip.io Home Based Dipstick Analyzer (first intervention) and by the ACON U500 Mission® U500 Urine Analyzer (comparative device - second intervention). Part of the participants (100 out of 302) were asked to perform the Dip.io urine test by themselves for the user performance evaluation.

Device: Dip.io Home Based Dipstick AnalyzerDevice: ACON U500 Mission® U500 Urine Analyzer

Interventions

First intervention (assigned to the "All participants" arm).

All participants (single arm)

Second intervention (assigned to the "All participants" arm).

All participants (single arm)

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subject is male or female, 18-80 years of age
  • Subjects who are healthy or pregnant; or
  • Subjects diagnosed with a disease that normally represents itself with an abnormal concentration of one of the following urine analytes; Glucose, Bilirubin, Ketone (Acetoacetic acid), Specific Gravity, Blood, pH, Protein, Urobilinogen, Leukocytes, and Nitrite (examples of such diseases include the following):
  • diabetes Type I, Type II, or gestational diabetes (Type III) or,
  • urinary tract infection (UTI)
  • heart disease
  • kidney disease
  • liver disease
  • pregnant women with preeclampsia, gestational diabetes or UTI
  • any pathological findings which might be identified by the urine test (according to the physician discretion)
  • Subject is capable and willing to provide informed consent.
  • Subject has facility with both hands.
  • Subject is capable and willing to adhere to the study procedures
  • Subject is familiar with the use of a smartphone.

You may not qualify if:

  • Subject has dementia.
  • Subject has mental disorders.
  • Subject is visually impaired (cannot read the user manual).
  • Subject cannot collect urine in receptacle.
  • Any other reason that might preclude the subject from the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Atlanta Center for Medical Research

Atlanta, Georgia, 30331, United States

Location

AccuMed Research Associates

Garden City, New York, 11530, United States

Location

MeSH Terms

Conditions

Urinary Tract InfectionsRenal InsufficiencyDiabetes Mellitus

Condition Hierarchy (Ancestors)

InfectionsUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesKidney DiseasesGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 17, 2016

First Posted

May 27, 2016

Study Start

October 1, 2015

Primary Completion

June 1, 2017

Study Completion

September 1, 2017

Last Updated

September 11, 2017

Record last verified: 2017-09

Data Sharing

IPD Sharing
Will not share

Locations